Biotech | March 01, 2022
AstraZeneca and Neurimmune enter licencing agreement to develop and commercialise NI006
Under the terms of the agreement, the upfront payment from Alexion to Neurimmune is US $ 30m
Under the terms of the agreement, the upfront payment from Alexion to Neurimmune is US $ 30m
The collaboration will leverage EdiGene’s expertise in high-throughput genome editing screening and Neukio’s strength in the development and manufacturing of induced pluripotent stem cell (iPSC) and natural killer cell (NK Cell)
In addition to its favourable activity profile, IBIO123 is formulated for administration by inhalation providing an efficient, rapid and non-invasive delivery method into the lungs via the respiratory tract
Investigational human monoclonal antibody in Phase Ib development for the treatment of transthyretin amyloid cardiomyopathy, a systemic, progressive and fatal condition
Sputnik Light has been authorised in more than 15 countries with the registration process ongoing in a further 30 countries
Researchers at the Feinstein Institutes administer extra vaccine doses as part of the NIH funded study
AdCOVID is a COVID-19 vaccine candidate that is administered via nasal spray.
Capital infusion to accelerate Earendil’s R&D platform
The Macau authorization followed a regulatory review that considered prior decisions by both the US FDA) and the European Medicines Agency
The approval of Cosentyx represents an important advancement for younger HS patients who have had limited treatment options
Subscribe To Our Newsletter & Stay Updated
